(Circulation. 2000;102:399.)
© 2000 American Heart Association, Inc.
Clinical Investigation and Reports |
Initial and 6-Month Results of Biodegradable Poly-l-Lactic Acid Coronary Stents in Humans
From the Department of Cardiology, Shiga Medical Center for Adults, Shiga, Japan (H.T., E.K., K.K, A.K., S.M., H.K., T.T., S.M., H.U.), and Igaki Medical Planning Co, Ltd, Kyoto, Japan (K.I.).
Correspondence to Hideo Tamai, MD, Department of Cardiology, Shiga Medical Center for Adults, 5-4-30, Moriyama, Moriyama, Shiga, Japan.
Background—Although metallic stents are effective in preventing acute occlusion and reducing late restenosis after coronary angioplasty, many concerns still remain. Compared with metallic stents, poly-l-lactic acid (PLLA) stents are biodegradable and can deliver drugs locally. The aim of this study was to evaluate the feasibility, safety, and efficacy of the PLLA stent.
Methods and Results—Fifteen patients electively underwent PLLA Igaki-Tamai stent implantation for coronary artery stenoses. The Igaki-Tamai stent is made of a PLLA monopolymer, has a thickness of 0.17 mm, and has a zigzag helical coil pattern. A balloon-expandable covered sheath system was used, and the stent expanded by itself to its original size with an adequate temperature. A total of 25 stents were successfully implanted in 19 lesions in 15 patients, and angiographic success was achieved in all procedures. No stent thrombosis and no major cardiac event occurred within 30 days. Coronary angiography and intravascular ultrasound were serially performed 1 day, 3 months, and 6 months after the procedure. Angiographically, both the restenosis rate and target lesion revascularization rate per lesion were 10.5%; the rates per patient were 6.7% at 6 months. Intravascular ultrasound findings revealed no significant stent recoil at 1 day, and they revealed stent expansion at follow-up. No major cardiac event, except for repeat angioplasty, developed within 6 months.
Conclusions—Our preliminary experience suggests that coronary PLLA biodegradable stents are feasible, safe, and effective in humans. Long-term follow-up with more patients will be required to validate the long-term efficacy of PLLA stents.
Key Words: angioplasty • stents • coronary disease
This article has been cited by other articles:
 |
|
 |
|
  J. A. Ormiston and P. W.S. Serruys Bioabsorbable Coronary Stents Circ Cardiovasc Interv, June 1, 2009; 2(3): 255 - 260. [Full Text] [PDF]
|
|
|
|
 |
|
 U Kaul and V Bhatia Choice of DES: is there a difference? Heart Asia, March 6, 2009; 2009(2): 11 - 15. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Maeng, L O Jensen, E Falk, H R Andersen, and L Thuesen Negative vascular remodelling after implantation of bioabsorbable magnesium alloy stents in porcine coronary arteries: a randomised comparison with bare-metal and sirolimus-eluting stents Heart, February 1, 2009; 95(3): 241 - 246. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Tanimoto, N. Bruining, R. T. van Domburg, D. Rotger, P. Radeva, J. M. Ligthart, and P. W. Serruys Late Stent Recoil of the Bioabsorbable Everolimus-Eluting Coronary Stent and its Relationship With Plaque Morphology J. Am. Coll. Cardiol., November 11, 2008; 52(20): 1616 - 1620. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. N. Helmus, D. F. Gibbons, and D. Cebon Biocompatibility: Meeting a Key Functional Requirement of Next-Generation Medical Devices Toxicol Pathol, January 1, 2008; 36(1): 70 - 80. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Daemen and P. W. Serruys Drug-Eluting Stent Update 2007: Part I: A Survey of Current and Future Generation Drug-Eluting Stents: Meaningful Advances or More of the Same? Circulation, July 17, 2007; 116(3): 316 - 328. [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Geraghty Bioabsorbable Stenting for Peripheral Arterial Occlusive Disease Perspectives in Vascular Surgery and Endovascular Therapy, December 1, 2006; 18(4): 295 - 298. [Abstract] [PDF]
|
|
|
|
 |
|
 D. R. Whittaker and M. F. Fillinger The Engineering of Endovascular Stent Technology: A Review Vascular and Endovascular Surgery, March 1, 2006; 40(2): 85 - 94. [Abstract] [PDF]
|
|
|
|
 |
|
 P. W. Serruys, M. J.B. Kutryk, and A. T.L. Ong Coronary-Artery Stents N. Engl. J. Med., February 2, 2006; 354(5): 483 - 495. [Full Text] [PDF]
|
|
|
|
|
|
M. A. Costa and D. I. Simon Molecular Basis of Restenosis and Drug-Eluting Stents Circulation, May 3, 2005; 111(17): 2257 - 2273. [Full Text] [PDF]
|
|
|
|
|
|
J. E. Sousa, M. A. Costa, E. M. Tuzcu, J. S. Yadav, and S. Ellis New Frontiers in Interventional Cardiology Circulation, February 8, 2005; 111(5): 671 - 681. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Lu, N. Zhuang, S.-S. Mao, J. Child, S. Carson, and M. J. Budoff Baseline Heart Rate-adjusted Electrocardiographic Triggering for Coronary Artery Electron-Beam CT Angiography Radiology, November 1, 2004; 233(2): 590 - 595. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Vogt, A. Stein, G. Rettemeier, N. Krott, R. Hoffmann, J. v. Dahl, A.-K. Bosserhoff, W. Michaeli, P. Hanrath, C. Weber, et al. Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent Eur. Heart J., August 1, 2004; 25(15): 1330 - 1340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B Heublein, R Rohde, V Kaese, M Niemeyer, W Hartung, and A Haverich Biocorrosion of magnesium alloys: a new principle in cardiovascular implant technology? Heart, June 1, 2003; 89(6): 651 - 656. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ozawa, D. A. G. Mickle, R. D. Weisel, N. Koyama, S. Ozawa, and R.-K. Li Optimal Biomaterial for Creation of Autologous Cardiac Grafts Circulation, September 24, 2002; 106(12_suppl_1): I-176 - I-182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Peuster, P Wohlsein, M Brugmann, M Ehlerding, K Seidler, C Fink, H Brauer, A Fischer, and G Hausdorf A novel approach to temporary stenting: degradable cardiovascular stents produced from corrodible metal---results 6-18 months after implantation into New Zealand white rabbits Heart, November 1, 2001; 86(5): 563 - 569. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E Regar, G Sianos, and P W Serruys Stent development and local drug delivery Br. Med. Bull., October 1, 2001; 59(1): 227 - 248. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. H. Baron Expandable Metal Stents for the Treatment of Cancerous Obstruction of the Gastrointestinal Tract N. Engl. J. Med., May 31, 2001; 344(22): 1681 - 1687. [Full Text] [PDF]
|
|
|
|
|
|
V. Sriram and C. Patterson Cell Cycle in Vasculoproliferative Diseases : Potential Interventions and Routes of Delivery Circulation, May 15, 2001; 103(19): 2414 - 2419. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Seabra-Gomes Radioactive stents to reduce restenosis: time for an epitaph? Eur. Heart J., April 2, 2001; 22(8): 621 - 623. [PDF]
|
|
|
|
 |
|
 Early Results with Biodegradable Stents Journal Watch Cardiology, September 29, 2000; 2000(929): 1 - 1. [Full Text]
|
|
|
|
|
|
A. Colombo and E. Karvouni Biodegradable Stents : "Fulfilling the Mission and Stepping Away" Circulation, July 25, 2000; 102(4): 371 - 373. [Full Text] [PDF]
|
|